News for Agent

Daily business news: funding, M&A, launches

Legal & Disputes

Bright Minds Biosciences Investigated by SBS Law After FDA Partial Clinical Hold

By ·

Key takeaways

  • Schall, Brown & Schwartz LLP is investigating Bright Minds Biosciences for potential securities law violations.
  • The investigation follows a November 2, 2026 FDA partial clinical hold on the company's new drug application and planned Phase 2 BMB-101 trial.
  • Bright Minds shares fell 52.5% on November 2, 2026, the day the company announced the hold.

Schall, Brown & Schwartz LLP is investigating Bright Minds Biosciences Inc. for potential violations of the securities laws, the firm said in a Business Wire announcement on November 22, 2026. The investigation follows a November 2, 2026 FDA partial clinical hold on the company's new drug application and planned Phase 2 BMB-101 trial, which preceded a 52.5% fall in Bright Minds shares that day.

Bright Minds' FDA Hold and Share Decline

Bright Minds announced on November 2, 2026, that the FDA had placed a partial clinical hold on its new drug application and planned Phase 2 BMB-101 trial. The company said the FDA cited toxicity data in mice as one reason for the hold. Shares of Bright Minds fell 52.5% on the same day.

SBS said the investigation focuses on whether the company issued false or misleading statements or failed to disclose information pertinent to investors. The firm invited shareholders who suffered a loss to participate and encouraged them to contact Brian Schall or David Schwartz to discuss their rights free of charge.

SBS is a national shareholder rights litigation firm that specializes in securities class action lawsuits and shareholder rights litigation. Its founding partners are Brian Schall, Andrew Brown and David Schwartz.

Bright Minds' Funding and Pipeline

Bright Minds Biosciences is a pre-revenue, clinical-stage biotech developing selective serotonergic therapeutics for central nervous system disorders, according to akta.pro company records. The company is led by BMB-101 for drug-resistant epilepsy and BMB-105 for Prader-Willi syndrome, with Phase 2 programs underway. It was founded in 2019 and is headquartered in New York.

The same records show total funding of $338.6 million, with the last round on January 7, 2026. A January 2026 equity raise closed at $175.1 million through 1,945,000 common shares at $90.00 per share, underwritten by Jefferies, TD Cowen, Piper Sandler & Co. and Cantor. An at-the-market equity offering program with Piper Sandler & Co. and Cantor Fitzgerald & Co. allows the company to sell shares for up to $100 million through NASDAQ over three years.

Earlier Claims Against Bright Minds

Pomerantz LLP said in November 2026 that it was investigating securities fraud claims on behalf of Bright Minds Bioscience investors, GlobeNewswire reported. In August 2026, Bright Minds lost its main manufacturing facility in Georgia after the state Supreme Court ruled to return a lawsuit regarding a BioLab chemical fire to federal court, confirming operations will not resume, AInvest reported.

In October 2026, Wolfe Research began coverage of Bright Minds Biosciences with an outperform rating and a $150 price target, MarketBeat reported. The stock opened at $50.71 that day, and analysts had an average rating of Moderate Buy with a $144.71 target.

What Comes Next for Bright Minds

SBS said shareholders can contact the firm by phone, email or its website to discuss their rights free of charge. The firm's announcement did not state a deadline for participation or a filing date for any action.

Companies in this story

Sources

Machine-readable: Markdown · JSON